Similar articles

• [Clinical problems of the natural coagulation and fibrinolysis inhibitors--introduction (author's transl)].

  Aoki N. Aoki N. Rinsho Ketsueki. 1978 Jul;19(7):917-9. Rinsho Ketsueki. 1978. PMID: 81326 Japanese. No abstract available.
• Plasma coagulation proteases, proteolytic inhibitors, and their interaction with platelets.

  Rao AK, Schmaier AH, Colman RW. Rao AK, et al. Pathobiol Annu. 1982;12:35-64. Pathobiol Annu. 1982. PMID: 6186978 Review. No abstract available.
• [Physiological anticoagulants. Current data on the composition, function and clinical value].

  Barkagan ZS, Bishevskii KM. Barkagan ZS, et al. Lab Delo. 1978;(10):579-87. Lab Delo. 1978. PMID: 81906 Review. Russian. No abstract available.
• [Changes in protein C inhibitor in disseminated intravascular coagulation: relationship with heparin cofactor II and alpha 2-plasmin inhibitor].

  Kazama Y, Takahashi K, Oguma Y, Sakuragawa N. Kazama Y, et al. Rinsho Ketsueki. 1988 Mar;29(3):344-8. Rinsho Ketsueki. 1988. PMID: 3398266 Japanese. No abstract available.
• On the significance of antithrombin-III, alpha 2-macroglobulin, alpha 2-antiplasmin, histidine-rich glycoprotein, and protein C in patients with acute myocardial infarction and deep vein thrombosis.

  Gram J, Jespersen J. Gram J, et al. Thromb Haemost. 1985 Aug 30;54(2):503-5. Thromb Haemost. 1985. PMID: 2417353